Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB081776, Pembrolizumab, and Palliative Radiation in Recurrent or Metastatic HNSCC
NCT06308913Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of INCB081776 in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Wisconsin–Madison. Primary endpoints: Incidence of Adverse Events up to 12 months, Duration of Adverse Events up to 12 months and 1 more. Started Sep 2024; status: completed.
02
Drugs
INCB081776
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06308913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308913.